Prospective Population-based Study of RSV-related Intermediate Care and Intensive Care Unit Admissions in Switzerland over a 4-Year Period (2001–2005)
Authors:
- The Swiss Pediatric Surveillance UnitTUThe Swiss Pediatric Surveillance Unit
- T. M. BergerTBT. M. Berger
- 9 December 2008
- journal article
- Published by Springer Nature in Infection
- Vol. 37 (2) , 109-116
Abstract
Respiratory syncytial virus (RSV) infections are a leading cause of hospital admissions in small children. A substantial proportion of these patients require medical and nursing care, which can only be provided in intermediate (IMC) or intensive care units (ICU). This article reports on all children aged < 3 years who required admission to IMC and/or ICU between October 1, 2001 and September 30, 2005 in Switzerland. We prospectively collected data on all children aged < 3 years who were admitted to an IMC or ICU for an RSV-related illness. Using a detailed questionnaire, we collected information on risk factors, therapy requirements, length of stay in the IMC/ICU and hospital, and outcome. Of the 577 cases reported during the study period, 90 were excluded because the patients did not fulfill the inclusion criteria; data were incomplete in another 25 cases (5%). Therefore, a total of 462 verified cases were eligible for analysis. At the time of hospital admission, only 31 patients (11%) were older than 12 months. Since RSV infection was not the main reason for IMC/ICU admission in 52% of these patients, we chose to exclude this subgroup from further analyses. Among the 431 infants aged < 12 months, the majority (77%) were former near term or full term (NT/FT) infants with a gestational age ≥ 35 weeks without additional risk factors who were hospitalized at a median age of 1.5 months. Gestational age (GA) < 32 weeks, moderate to severe bronchopulmonary dysplasia (BPD), and congenital heart disease (CHD) were all associated with a significant risk increase for IMC/ICU admission (relative risk 14, 56, and 10, for GA ≤ 32 weeks, BPD, and CHD, respectively). Compared with NT/FT infants, high-risk infants were hospitalized at an older age (except for infants with CHD), required more invasive and longer respiratory support, and had longer stays in the IMC/ICU and hospital. In Switzerland, RSV infections lead to the IMC/ICU admission of approximately 1%–2% of each annual birth cohort. Although prematurity, BPD, and CHD are significant risk factors, non-pharmacological preventive strategies should not be restricted to these high-risk patients but also target young NT/FT infants since they constitute 77% of infants requiring IMC/ICU admission.Keywords
This publication has 49 references indexed in Scilit:
- Genetic Susceptibility to Respiratory Syncytial Virus Bronchiolitis Is Predominantly Associated with Innate Immune GenesThe Journal of Infectious Diseases, 2007
- Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemicsEuropean Journal of Pediatrics, 2007
- Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk ChildrenPharmacoEconomics, 2007
- Hospitalization for respiratory syncytial virus among California infants: Disparities related to race, insurance, and geographyThe Journal of Pediatrics, 2006
- Bronchodilators for bronchiolitis2006
- Recomendaciones para la prevención de la infección por virus respiratorio sincitialAnales de Pediatría, 2005
- Anticholinergic drugs for wheeze in children under the age of two yearsCochrane Database of Systematic Reviews, 2005
- Palivizumab for preterm infants. Is it worth it?Archives of Disease in Childhood - Fetal and Neonatal Edition, 2005
- Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus InfectionsPediatrics, 2003
- Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart diseaseThe Journal of Pediatrics, 2003